The pharmaceutical industry is embracing artificial intelligence (AI) with the potential to accelerate drug development timelines and reduce costs, according to Sandy Donaldson, cofounder and president of Impiricus, a health technology company. Speaking about the industry’s evolving landscape, Donaldson noted that while the sector has historically faced strict regulations and calls for transparency, the integration of AI is helping to streamline operations across the entire pharmaceutical lifecycle.
In recent years, the application of AI has expanded beyond clinical development into manufacturing, laboratory operations, and supply chain management, impacting how drugs are brought to market. Donaldson, who collaborates with 30 of the top pharmaceutical companies, indicated that this shift has been particularly evident over the last two years. “AI will help reduce the cycle to bring drugs to market,” he explained.
However, as the pharmaceutical sector adopts these advanced technologies, it is also navigating increasing government oversight. Although there is currently no comprehensive federal framework governing AI in pharmaceuticals, both state and European Union regulations are tightening. “What we’re seeing is an increased focus on government controls, explainability of decisions, and traceability of audit trails,” Donaldson added. This regulatory environment adds complexity to the integration of AI solutions.
Despite these challenges, the implications of AI in drug development are promising. By fostering improved accuracy in drug development processes, it is likely that more orphan drugs will reach the market, addressing unmet medical needs for thousands of chronic diseases that currently lack effective treatments. The increased efficiency provided by AI could also mean a reduction in the overall costs associated with drug development.
The industry is aware of the cultural barriers that may impede technological adoption. Donaldson pointed out the prevalent “Not Invented Here” syndrome, a mindset that often leads companies to believe their existing processes are optimal. “Pharma companies know they need to change their culture,” he stated, highlighting a significant shift that is necessary for the industry to fully benefit from AI innovations.
As AI continues to shape the future of pharmaceuticals, it has already begun driving substantial investments in healthcare technology. Reports suggest that AI could trigger a $1 billion shift in healthcare as companies look for ways to harness its capabilities. With the industry at a crossroads, the adoption of AI is enabling greater collaboration among payers, providers, and pharmaceutical companies, positioning them to lead in AI implementation.
For further insights, listeners can check out Donaldson’s conversation with Susan Morse, executive editor of Healthcare Finance News, where they delve into the implications of AI on healthcare.
As the landscape evolves, the pharmaceutical sector’s embrace of AI offers a glimpse into a future where drug development is faster, more efficient, and possibly more affordable. This shift not only holds promise for the industry but also for patients seeking new treatment options, marking a pivotal moment in healthcare innovation.
See also
Nadella Reveals AI Copilot Fails Basic Tasks, Calls for New Frameworks Despite $80B Investment
US Congressman Burchett Spreads AI-Generated Video Falsely Attributing Comments to Jack White
AI Transforms Workplaces: Enhancing Human Skills While Mitigating Job Fears
AI-Driven Multiomics Revolutionizes Drug Discovery, Tackling Data Fragmentation Challenges
AI Impact Summit 2026: India Leads Global Dialogue on Workforce Reskilling Amid AI Automation
